SAN FRANCISCO, Oct. 14 /PRNewswire-FirstCall/ -- Medizone International, Inc. (OTC Bulletin Board: MZEI) announces that a third round of AsepticSure(TM) trials have begun at Innovation Park, Queen's University. Building on the results obtained during the first and second round of laboratory testing, this third round is being conducted to establish the precise protocols necessary in order to obtain maximum bactericidal action in combination with minimum turn-around times in keeping with normal hospital flow patterns. Simultaneously, a development prototype is being finalized in order to conduct a full room scale hospital mock up.
Medizone's CEO Edwin Marshall stated, "While this stage of the development program has taken a bit longer than we envisioned, we expect the results to be well worthwhile. It is now clear the integration of technology involved, combined with the scientific data that continues to be gathered, should not only establish Medizone's AsepticSure(TM) system as the global standard for hospital and infrastructure decontamination, but with additional state of the art interlocking patent opportunities being developed, should offer the company exceedingly strong patent protection for this emerging technology."
Medizone International, Inc., is a research and development company engaged in developing its AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. The trial program has been expanded in final preparation for a hospital mock-up, intended to be followed by hospital beta testing. It is estimated hospitals deploying the AsepticSure(TM) system will save $6 to $7 for each $1 invested while preventing tens of thousands of hospital acquired infections.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Investor Relations: 415-868-0300 / web site: www.medizoneint.com E-mail: firstname.lastname@example.org
SOURCE Medizone International, Inc.
|SOURCE Medizone International, Inc.|
Copyright©2009 PR Newswire.
All rights reserved